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Abstract
This controlled laboratory study demonstrated 
the residual speed of efficacy of an imidacloprid/
flumethrin collar (Seresto®, Bayer) for the con-
trol of ticks (Dermacentor variabilis, Amblyomma 
americanum) at 6 and 12 hours post-infestation on 
dogs when compared to oral fluralaner (Bravecto®, 
Merck). Dogs were randomised by pre-treatment 
tick counts: Group  1) imidacloprid 10 % (w/w)/
flumethrin 4.5 % (w/w) collar, 2) fluralaner (dos-
age 25.1 – 49.4 mg/kg), and 3) non-treated controls. 
Ticks (50/species/dog) were infested on days 3, 14, 
21, 28, 42, and 56 followed by 50 D. variabilis on 
days 70 and 84. Live and dead attached ticks were 
counted 6 and 12 hours later. Efficacy against both 
species at 6 and 12 hours for Group 1 was 94 – 100 %. 
Efficacy for Group 2 against both species at 6 hours 
was 4 – 69 %; efficacy at 12 hours was 8 – 100 %. Live 
(attached and non-attached) tick counts at 6 hours 
in Group 1 were significantly lower (p ≤ 0.05) than 
counts in Group 2 and 3 on all days. At 12 hours, 
live counts were significantly lower (p ≤ 0.05) in 
Group 1 than Group 2 for D. variabilis from days 
56 – 84 and for A. americanum from days 28 – 56. 
There were significantly fewer (p ≤ 0.05) total ticks 
(total live and dead attached) on dogs in Group 1 
compared to Group 2 and 3 at all time points. This 
study demonstrated that an imidacloprid/flume-
thrin collar was highly efficacious (94 – 100 %) at 
repelling and killing ticks on dogs at 6 and 12 hours 
post-infestation and was more efficacious than flu-





Ticks are persistent and hardy arachnids that 
pose a danger to humans and their pets through 
tick-borne diseases. The myriad of tick species and 
wide variety of tick lifestyles makes them difficult 
to control in domestic animals, and their ability 
to survive adversity allows them to successfully 
follow their hosts into new and diverse habitats. 
Those traits, along with other factors such as habi-
tat destruction, climate change, and pet portabil-
ity, will likely increase encounters between ticks 
and pets in the future (Bacon et al. 2008; Chomel 
2011; Diuk-Wasser et al. 2012; Hamer et al. 2010).
New information is continually being learned 
regarding tick-borne diseases in the medical and 
veterinary communities. For instance, ticks carry 
many different vector-borne diseases, and it is now 
known that a single tick may carry and transmit 
more than one pathogen at each feeding (Williams-
Newkirk et al. 2014). New tick-borne pathogens 
have also been discovered, such as the Bourbon 
virus in 2014 and the Heartland virus in 2012 
(Kosoy 2015; McMullan et al. 2012). Also, older 
tick-borne organisms, previously thought to be non-
pathogenic, are now being considered as pathogenic 
(Krause et al. 2015). Furthermore, traditional 
transmission times of some tick-borne illnesses, 
such as Lyme disease, are being questioned and 
may be shorter than previously considered (Cook 
2015). All of these factors make acaracide kill times 
especially important in the prevention of tick-borne 
diseases as there are significant risks involved with 
the feeding of even one tick.  
The imidacloprid/flumethrin collar (Seresto®, 
Bayer) was introduced in the United States in 
2013. It is an innovative flea and tick collar with 
unique technology to protect dogs and cats from 
fleas and ticks for 8 months. The active ingredi-
ents in the collar are released slowly onto the skin 
and hair of the pet, providing both repel and kill 
properties through contact with the active ingredi-
ents. Therefore, fleas and ticks do not have to bite 
or attach in order to die, an important feature in 
the prevention of vector-borne diseases. Also, the 
8 month duration of protection with only one appli-
cation can aid in owner compliance through ease 
of use. Fluralaner (Bravecto®, Merck) is another 
commercially available product that kills fleas and 
ticks; however, there is no evidence for repellent 
activity. Oral products, with a systemic distribu-
tion, require both fleas and ticks to penetrate the 
skin and initiate the feeding process in order to 
contact the active ingredient. This may enable 
Fig. 1 Male (below) and female (above) Dermacentor 
variabilis 




transmission of disease-causing organisms before 
the parasite is killed. This randomised controlled 
comparative laboratory study was designed to 
evaluate the residual speed of efficacy of Seresto® 
for the control of Dermacentor variabilis (Fig. 1) 
and Amblyomma americanum (Fig. 2) ticks at 6 and 
12 hours post-infestation on dogs when compared to 
2 competitive products and a non-treated negative 
control; results from 3 groups are reported here.
Materials and methods
Animals
Dogs were included in the study if they were over 
6 months of age, determined to be healthy based on 
physical examination, not pregnant, were able to 
harbor an adequate tick infestation, and were not 
exposed to a previous insecticide/acaracide within 
90 days of study onset. Forty-eight dogs were ini-
tially evaluated for the ability to harbor adequate 
tick infestations. All dogs were infested with 
approximately 50 D. variabilis on study day-7 with 
tick counts performed 48 hours later. Dogs were 
then ranked by live tick counts in descending order 
and randomised in sets of 4. The 8 dogs with the 
lowest tick counts were not included in the study. 
The results from 3 groups of 10 animals, Group 1) 
Seresto®, Group 2) Bravecto®, and Group 3) non-
treated controls, are reported here. The fourth 
group, afoxolaner (NexGard®, Merial), along with 
dogs in Groups 1 and 3 are presented in a separate 
manuscript.
Products
Both products were administered according to the 
label directions and weight of each dog prior to 
treatment. On day 0, Seresto® collars, imidacloprid 
10 % (w/w)/flumethrin 4.5 % (w/w), were applied to 
all dogs in Group 1. The length was adjusted, in 
accordance with the label, and the extra length cut 
off and secured with a ratchet mechanism. Collars 
were applied according to the dog’s bodyweight 
(collar dose ranges: small collar < 18 lbs, large 
collar > 18 lbs). Group 2 dogs were treated orally 
with Bravecto® at a dosage of 25.1 – 49.4 mg/kg 
bodyweight. Two size chewable tablets were avail-
able and dosed based on bodyweight: 250 mg and 
500 mg. The control group remained non-treated. 
Experimental infestations
Dogs were infested with D. variabilis and A. ameri-
canum based on a predetermined schedule. Each 
infestation consisted of approximately 50 ticks of 
each species applied along the dog’s dorsal midline 
from shoulders to hips.  
Experimental design
This laboratory study was conducted in accordance 
with VICH GL9 Good Clinical Practices (GCP), 
June 2000 (FDA Guidance for Industry 85, May 
2001) and applicable standard operating proce-
dures. Dogs were housed individually in runs 
throughout the study. They were bathed with a 
mild, non-medicated shampoo, combed thoroughly, 
and allowed to acclimate for 11 days prior to prod-
uct administration. Concomitant treatments were 
prohibited except where deemed necessary and 
would not influence the performance of any product. 
Following product administration, 50 D. variabilis 
and 50 A. americanum were infested per dog on 
days 3, 14, 21, 28, 42, and 56 followed by infesta-
tion with only 50 D. variabilis on days 70 and 84. 
This schedule was created due to the fact that flu-
ralaner is only labeled against A. americanum for 
8 weeks. Tick counts were performed at 6 hours 
(thumb count) and 12 hours (full body comb count 
with tick removal) following infestation to assess 
the speed of repellency and/or kill; all ticks on the 
dogs were counted including both live (attached 
and non-attached) and dead attached ticks.
Clinical monitoring
During acclimatisation, dogs were observed at least 
once daily. A physical examination was performed 
to verify health status during the acclimatisation 
period. For the remainder of the study, dogs were 
observed daily until study completion, at which 
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time all dogs were returned to the supplier. On 
study day 0, dogs were also observed 2 and 4 hours 
after product administration for adverse events. 
Efficacy determination
Total live (attached and non-attached) and dead 
attached tick counts were determined and recorded. 
Individual live tick counts were used to calculate a 
geometric mean (GM) for each group at each time 
point on the specified study days. For each post-
treatment tick count, efficacy was calculated using 
Abbott’s Formula. Percent efficacy (% reduction) 
was determined by comparing the GM number of 
live ticks retained on the treated group to the GM 
number of live ticks retained on the non-treated 
negative control group using the following formula:
% efficacy =
GM tick count control − GM tick count (treatment)
GM tick count(control)
Data analysis
For D. variabilis, the assumption of equally distrib-
uted tick-ridding ability was assessed by descrip-
tively summarising the pre-study tick counts. The 
statistical method comparing post-treatment tick 
counts utilised the pre-study tick counts for each 
animal. The efficacy of the treated groups, relative 
to the control group, was computed with Abbott’s 
formula. Arithmetic mean counts and geometric 
Table 1  Dermacentor variabilis efficacy and geometric mean live (attached and non-attached), dead attached, and total 
(total live and dead attached) tick counts after treatment with Seresto® or Bravecto®
Study Day Day 3 Day 14 Day 21 Day 28 Day 42 Day 56 Day 70 Day 84
Hours post-
infestation
6h 12h 6h 12h 6h 12h 6h 12h 6h 12h 6h 12h 6h 12h 6h 12h
Seresto® 
Mean # live 1.5c 1.0b 0.0c 0.0b 0.2b 0.0b 0.1b 0.1b 0.0b 0.0b 0.0b 0.0c 0.0b 0.0b 0.1b 0.0b
Mean # dead 
attached 0.1
ab 1.1a 0.8ab 0.5a 0.3a 0.5a 0.2a 0.2a 0.1a 0.1a 0.2a 0.2a 0.9b 0.3ab 0.3a 0.0a
Mean # total 1.6b 2.1b 0.8b 0.5c 0.4b 0.5b 0.2b 0.2c 0.1b 0.1c 0.2b 0.2b 0.9b 0.3b 0.4b 0.0b
% Efficacyd 94.9 97.0 100 100 99.0 100 99.7 99.8 100 100 100 100 100 100 99.6 100
Bravecto®
Mean # live 9.1b 0.6b 5.9b 0.0b 7.4a 0.3b 13.5a 0.9b 14.1a 0.7b 12.3a 3.9b 16.4a 10.5a 19.8a 25.8a
Mean # dead 
attached 1.9
b 11.3b 2.5b 10.0b 1.1a 9.2b 0.2a 9.9b 0.1a 8.3b 0.2a 5.7b 0.0a 2.3b 0.2a 0.3a
Mean # total 12.6a 12.4a 9.2a 10.0b 10.8a 9.9a 13.8a 11.5b 14.3a 9.5b 12.5a 11.2a 16.4a 16.0a 20.1a 27.1 a
% Efficacyd 68.0 98.3 68.6 100 62.7 98.8 35.4 96.8 20.7 97.2 14.7 82.5 12.4 62.7 5.0 8.5
Control
Mean # live 28.5a 34.6a 18.9a 29.2a 19.8a 29.0a 20.9a 29.6a 17.8a 26.2a 14.5a 22.4a 18.8a 28.1a 20.9a 28.1a
Mean # dead 
attached 0.0
a 0.0a 0.2a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a
Mean # total 28.5a 34.6a 19.3a 29.2a 19.8a 29.0a 20.9a 29.6a 17.8a 26.2a 14.5a 22.4a 18.8a 28.1a 20.9a 28.1a
a,b,c  Values down columns with unlike superscripts are significantly different (p < 0.05)
d % Efficacy calculated using Abbott’s Formula
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 
attached due to the mathematical basis for calculating geometric means.
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means were both used in the efficacy calculation. 
Geometric means were calculated following trans-
formation using a logarithmic method (averaging 
the transformed values, and converting the aver-
age using antilog to represent a geometric mean). 
Because some animals might have had zero (0) tick 
counts, all counts were modified by adding one (1) 
to each prior to logarithmic transformation. Also, 
one (1) was subtracted from the antilog value to 
meaningfully represent the geometric mean for 
each group. Only live tick counts were used to cal-
culate efficacy.
Live, dead attached, and total (total live and dead 
attached) tick counts for each species were ana-
lysed separately. Log (tick counts+1) were analysed 
with a repeated measures analysis of covariance 
(RMANCOVA) including terms for treatment 
(TRT), animal (random), study day (DAY), and 
the interaction of treatment and study day (TRT 
x DAY), using the pre-treatment tick counts as a 
covariate (for D. variabilis only, no baseline covari-
ate when analysing for the other tick species). SAS 
PROC MIXED (SAS® Institute, Cary, NC) was used 
for analysis with the covariance structures ‘AR(1)’ 
and ‘ARH(1)’ for data collected on equal intervals, 
or ‘CS’ and ‘CSH’ for data collected on unequal 
intervals. Results from the model with the smallest 
Akaike’s Information Criterion were used. 
If the interaction of treatment and study day was 
significant at the 0.05 level, multiple group pairwise 
comparisons were generated using a Bonferroni 
alpha adjustment for multiple group comparisons. 
Table 2  Amblyomma americanum efficacy and geometric mean live (attached and non-attached), dead attached, and 
total (total live and dead attached) tick counts after treatment with Seresto® or Bravecto®
Study Day Day 3 Day 14 Day 21 Day 28 Day 42 Day 56
Hours  
post-infestation
6h 12h 6h 12h 6h 12h 6h 12h 6h 12h 6h 12h
Seresto® 
Mean # live 0.7b 0.2b 0.0b 0.0b 0.1b 0.1b 0.1b 0.0c 0.2b 0.0b 0.2b 0.0b
Mean # dead attached 0.2a 0.7a 1.1a 0.7a 0.7a 0.4a 0.3a 0.3a 0.4a 0.2a 0.4a 0.2a
Mean # total 1.0b 0.9b 1.1b 0.7b 0.7b 0.4b 0.4b 0.3b 0.7b 0.2b 0.5b 0.2b
% Efficacyd 94.2 98.4 100 100 99.6 99.7 99.5 100 98.7 100 98.8 100
Bravecto®
Mean # live 5.4a 0.5b 5.6a 1.5b 8.3a 1.4b 9.8a 3.8b 11.5a 10.9a 13.1a 11.2a
Mean # dead attached 1.1a 9.4b 1.0a 8.4b 0.8a 10.7b 0.2a 10.6b 0.3a 4.8b 0.4a 2.9b
Mean # total 7.8a 10.5a 7.1a 10.7a 10.7a 13.1a 10.3a 16.1a 12.0a 18.8a 13.6a 14.8a
% Efficacyd 55.5 96.8 35.1 84.9 57.3 94.2 35.3 82.5 33.3 49.8 4.2 33.6
Control
Mean # live 12.2a 14.4a 8.6a 9.6a 19.4a 23.4a 15.1a 21.8a 17.3a 21.8a 13.7a 16.8a
Mean # dead attached 0.0a 0.0a 0.12a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a 0.0a
Mean # total 12.2a 14.4a 8.8a 9.6a 19.4a 23.4a 15.1a 21.8a 17.3a 21.8a 13.7a 16.8a
a,b,c Values down columns with unlike superscripts are significantly different (p < 0.05)
d % Efficacy calculated using Abbott’s Formula
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 
attached due to the mathematical basis for calculating geometric means.
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These simple effect pairwise comparisons were 
obtained from the TRT x DAY interaction. If the 
interaction term was not significant (p > 0.05), the 
TRT main effect was evaluated. If the TRT main 
effect was not significant (p > 0.05), the results were 
deemed not significant and no further analyses were 
conducted. If the TRT main effect was significant 
(p ≤ 0.05), multiple group pairwise comparisons were 
 generated using a Bonferroni alpha adjustment for 
multiple group comparisons across the pooled time 
points. In addition, dead attached ticks and total 
ticks were compared across groups. However, pre-
treatment D. variabilis counts were not used as a 
covariant when dead attached or total ticks were 
analysed. All four treatment groups were analysed 
together, however only the results from Groups 1, 2 
and 3, are reported here. Software from SAS® Insti-
tute, Cary, NC version 9.3 was used for all analyses.
Results
Thirty dogs (11 female and 19 males) were included 
in Groups 1, 2 and 3. All dogs were over 6 months 
of age and ranged in weight from 5.3 – 15.2 kg. Dogs 
were dosed according to the label directions for each 
product. In Group 1, there was 1 dog treated with 
the small dog Seresto® collar (< 18 lbs) and 9 dogs 
were treated with the large dog collar (> 18 lbs). 
In Group  2, the Bravecto® dosage ranged from 
25 – 49.3 mg/kg. There were no adverse events dur-
ing the study. One dog in Group 1 was removed on 
study day 34 due to the fact that the dog removed 
and destroyed its collar. 
Efficacy against D. variabilis at 6 hours for 
Group 1 was 95 – 100 % and for Group 2 was 5 – 69 % 
(Table 1, Fig. 3); efficacy at 12 hours for Group 1 was 
97 – 100 % and for Group 2 was 8 – 100 % (Table 1, 
Fig. 4). Efficacy against A. americanum at 6 hours 
for Group 1 was 94 – 100 % and for Group 2 was 
4 – 57 % (Table 2, Fig. 5); efficacy at 12 hours 
for Group 1 was 98 – 100 % and for Group 2 was 
34 – 97 % (Table 2; Fig. 6). The majority of live ticks 
on the Bravecto treated dogs at 6 hours post-infes-
tation were attached to the dogs and not loose on 
the body (average for D. variabilis: 58 %–99 % and 
A. americanum: 77–95 %); at 12 hours, an average of 
> 99 % of live ticks on Bravecto dogs were attached 
and feeding (except day 3 which was 40 %). Live 
(attached and non-attached) tick counts at 6 hours 
for both species in Group 1 were significantly lower 
(p ≤ 0.05) than counts in Group 2 and 3 on all chal-
lenge days. At 12 hours, live D. variabilis counts 
were significantly lower (p ≤ 0.05) in Group 1 as 
compared to Group 2 from days 56 – 84 and against 
A. americanum from days 28 – 56. Also, there were 
significantly fewer (p ≤ 0.05) total ticks (total live 
and dead attached) of each species on the dogs in 
Group 1 compared to Group 2 and 3 at all time points 
(Table 1 – 2, Fig. 7 – 10). When the two species were 
combined (sum total of average of D. variabilis and 
A. americanum), total tick counts for Group 1 were 
at most only 3.0 ticks/dog, whereas Group 2 reached 
28.3 ticks/dog, and Group 3 reached 52.4 ticks/dog. 
Discussion
In this study, Seresto® was consistently efficacious 
over the entire study period at both time points and 
for both tick species, exhibiting a rapid speed of 
contact kill as well as repellency. Additionally, no 
adverse events were reported for Seresto®, further 
Table 3  Sequence of events leading to successful feeding 
of ticks (Anderson and Magnarelli 2008)
Appetence Hunting or seeking host
Engagement 
Adherence to the skin  
or fur of the host
Exploration
Searching on the skin  
for suitable attachment site
Penetration
Insertion of the mouthparts into the 
host’s epidermis and dermis
Attachment Feeding site established
Ingestion Uptake of blood and other fluids
Engorgement 
Partial or complete meals  
of blood taken
Detachment Withdrawal of the mouthparts
Disengagement Tick drops off of the host
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supporting the safety of the product. Results from 
previous Seresto® efficacy studies agree with the 
results found here. In a field trial, in which dogs 
were naturally infected with ticks, Seresto® treated 
dogs had a high percentage of efficacy ranging from 
91.2 – 100 % over the 8 month period (Stanneck et al. 
2012). In a laboratory study, in which dogs were 
repeatedly re-infested with Rhipicephalus san-
guineus, the protective 6 hour efficacy of Seresto® 
was 85.6 % on day 7 and 90.1 – 97.1 % from day 14 to 
Fig. 3 Efficacy 6 hours post-infestation with D. variabilis after treatment with Seresto® or Bravecto®
*  Live tick counts significantly different (p ≤ 0.05) as compared to Bravecto® group
†  Live tick counts significantly different (p ≤ 0.05) as compared to control group
a  % Efficacy calculated using Abbott’s Formula
Fig. 4 Efficacy 12 hours post-infestation with D. variabilis after treatment with Seresto® or Bravecto®
*  Live tick counts significantly different (p ≤ 0.05) as compared to Bravecto® group
†  Live tick counts significantly different (p ≤ 0.05) as compared to control group
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the end of the study (day 70).  In the same study, 
the protective 18 hour tick efficacy was 98 – 99.6 % 
during the entire study period (Horak et al. 2012). 
The results presented here illustrate the rapid 
repellent properties of Seresto® by inhibiting 
almost all ticks from attaching and feeding with-
in 6 hours of infestation. Ticks that are repelled 
and killed are unable to attach and feed, therefore 
decreasing the risk of disease-causing organism 
transmission. The authors’ have experienced the 
Fig. 6 Efficacy 12 hours post-infestation with A. americanum after treatment with Seresto® or Bravecto®
*  Live tick counts significantly different (p ≤ 0.05) as compared to Bravecto® group
†  Live tick counts significantly different (p ≤ 0.05) as compared to control group
a  % Efficacy calculated using Abbott’s Formula
Fig. 5 Efficacy 6 hours post-infestation with A. americanum after treatment with Seresto® or Bravecto®
* Live tick counts significantly different (p ≤ 0.05) as compared to Bravecto® group
† Live tick counts significantly different (p ≤ 0.05) as compared to control group
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same repellent properties in clinical observations. 
Ticks on Seresto® treated dogs appear uncomforta-
ble and irritated almost immediately and are found 
crawling aimlessly on the haircoat until they fall 
off of the dog and are killed. The World Association 
for the Advancement of Veterinary Parasitology 
(WAAVP) guidelines further characterised this 
repellent action (Marchiondo et al. 2013). These 
guidelines characterize sensu stricto repellency 
with ticks that are found either moving away from 
Fig. 7 Dermacentor variabilis 6 hour geometric mean live (attached and non-attached) and dead attached tick counts 
after treatment with Seresto® or Bravecto®
*  Total tick counts significantly different (p < 0.05) as compared to Bravecto® group
†  Total tick counts significantly different (p < 0.05) a compared to control group
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 






























Fig. 8 Dermacentor variabilis 12 hour geometric mean live (attached and non-attached) and dead tick counts after 
treatment with Seresto® or Bravecto®
*  Total tick counts significantly different (p < 0.05) as compared to Bravecto® group
†  Total tick counts significantly different (p < 0.05) as compared to control group
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 
































the treated animal or that fall off within 6 – 8 hours 
after contact with treated haircoat, both charac-
teristics of ticks applied to Seresto® treated dogs.
Repellency and/or a rapid speed of kill are more 
important now than ever before. Ticks may 
transmit pathogens to hosts much faster than pre-
viously considered (Fourie et al. 2013b). Recom-
mendations from the Canine Vector-Borne Disease 
world forum in 2011 (CVBD) note that pathogen 
transmission can occur almost immediately from 
Fig. 9 Amblyomma americanum 6 hour geometric mean live (attached and non-attached) and dead attached tick 
counts after treatment with Seresto® or Bravecto®
*  Total tick counts significantly different (p < 0.05) as compared to Bravecto® group
† Total tick counts significantly different (p < 0.05) as compared to control group 
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 






























Fig. 10 Amblyomma americanum 12 hour geometric mean live (attached and non-attached) and dead attached tick 
counts after treatment with Seresto® or Bravecto®
*  Total tick counts significantly different (p < 0.05) as compared to Bravecto® group
†  Total tick counts significantly different (p < 0.05) as compared to control group 
Note: Geometric Mean # totals are not expected to equal the sum of geometric mean # live + geometric mean # dead 
































some ticks, and the concept of repellency is impor-
tant to avoid blood meals by arthropod vectors 
(Baneth et al. 2012). Using a product with repel-
lent properties, such as Seresto®, can inhibit ticks 
from attaching and feeding, therefore aiding in the 
prevention of disease transmission. While this was 
not a disease transmission study, several studies 
have successfully confirmed the ability of Seresto® 
to help prevent the transmission of disease-causing 
organisms to dogs and cats including: Ehrlichia 
canis, Babesia canis, Babesia vogeli, Anaplasma 
platys, and Cytauxzoon felis (Dantas-Torres et al. 
2013; Fourie et al. 2013a; Reichard et al. 2013; 
Stanneck and Fourie 2013).
A product that offers repellency and/or a rapid 
speed of kill may also reduce the likelihood of 
transmission of pathogens between ticks. Some 
species of tick-borne pathogens benefit from co-
feeding, which allows the pathogen to be transmit-
ted from tick to tick without systemic transmission 
to the host. First described in tick borne encepha-
litis virus transmission (Labuda et al. 1996), ticks 
who feed either in physical proximity or temporal 
proximity can share pathogens on the skin sur-
face at bite sites, eliminating the need to transmit 
the pathogen to the host first. The importance of 
this transmission process is still being explored in 
other pathogens (Harrison and Bennett 2012). Tick 
prevention products with rapid contact repellency 
and/or kill have the best chance of preventing the 
transmission of pathogens between ticks in either 
systemic or co-feeding paradigms. This will in turn, 
reduce the number of infected ticks in the environ-
ment and therefore, the risk of tick-borne infections 
in humans and pets.
There are 9 steps that occur during the feeding pro-
cess of a tick (Table 3) (Anderson and Magnarelli 
2008). For orally administered, systemically active 
products, such as Bravecto®, the tick must pene-
trate the skin with its mouthparts and ingest the 
active ingredient through the hypostome (Fig. 11) 
from the vascular compartment of the dog in order 
to die; therefore, the feeding process is not inter-
rupted until steps 5 – 7 (attachment, ingestion, 
and engorgement). On the other hand, products 
that repel ticks can target the feeding process as 
early as steps 2 – 3 (engagement and exploration). 
This difference in disruption of the feeding process 
between topically versus systemically active prod-
ucts is reflected in this study by the total (total live 
and dead attached) tick counts on the dogs. Dogs 
treated with Seresto® had significantly fewer total 
ticks on them at 6 and 12 hours post-infestation on 
all challenge days compared to dogs treated with 
Bravecto®. When the 2 species were combined, 
the sum of the mean total number of ticks on the 
Seresto® treated dogs was at most only 3.0 ticks/
dog compared to 28.3 ticks/dog in the Bravecto® 
group. The repellent activity of Seresto® affected 
the feeding process earlier, significantly reducing 
the number of ticks on the dogs and the number 
of ticks that could penetrate the skin and attach 
compared to dogs treated with Bravecto®.
No repellent activity was observed in dogs treated 
with Bravecto®, which would be expected with a 
systemically active product. At 6 hours post-infes-
tation, most of the ticks on the dogs remained alive. 
During the first part of the study, a large portion 
of those ticks were dead at 12 hours, however, they 
remained attached to the dogs. Over time, the ticks 
weren’t killed within 12 hours. The number of live 
attached ticks on Bravecto® treated dogs 12 hours 
Fig. 11 Amblyomma americanum mouthparts (hypos-
tome, chelicerae, and palps
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post-infestation increased with a corresponding 
decrease in efficacy down to 8.5 % for D. variabi-
lis (at 12 weeks) and 33.6 % for A. americanum (at 
8 weeks). This decrease in efficacy of Bravecto® over 
a 12 week study period was also observed 24 hours 
post-infestation with Dermacentor reticulatus (a 
species not found in North America) and R. san-
guineus (Beugnet 2015). It can be presumed that 
as the active ingredient is cleared from the body, 
the plasma levels decrease and the feeding time 
required to kill a tick increases. The longer a tick 
remains attached and feeds on a dog, the higher the 
risk for transmission of disease-causing organisms. 
Attached and feeding ticks are not only a serious 
concern due to the pathogens they can transmit, 
they can also lead to other medical and cosmetic 
issues. Tick bites can lead to irritation and pruritus 
at the attachment site, secondary infections requir-
ing medical treatment, and a variety of toxic or 
allergic reactions, some of which can be life threat-
ening (CAPC 2011; CDC 2014). Treatment for these 
signs will be an additional expense for owners and 
additional stress for the pet. Attached ticks on a pet 
can also harm the human animal bond, but more 
importantly, can be a potential concern for owners 
in terms of exposure to disease-causing organisms 
during the removal and discard process if proper 
precautionary measures are not taken.
It should be noted that the WAAVP guidelines 
suggest that tick efficacy be determined 48 hours 
after an infestation and in special circumstances 
(systemic products or when taking into account 
the potential transmission of pathogens) efficacy 
determination may be delayed until 72 hours (Mar-
chiondo et al. 2013). Therefore, despite the risk of 
transmission of disease-causing organisms within 
these long time periods, the purpose of this study 
was not to discredit the actual label claims for 
Bravecto®. The purpose was to determine the speed 
of repellency and/or kill of both products. Further 
studies should be performed to determine the effect 
of Bravecto® treatment on disease transmission.
Conclusion
This study demonstrated that Seresto® (an imida-
cloprid/flumethrin collar) was highly efficacious 
(94 – 100 %) at repelling and killing D. variabilis 
and A. americanum ticks on dogs at 6 and 12 hours 
post-infestation and was significantly more effi-
cacious (p ≤ 0.05 based on live tick counts) than 
Bravecto® (fluralaner) at the earlier time point 
(6 hours). The efficacy of Seresto® was also signifi-
cantly higher (p ≤ 0.05 based on live tick counts) 
than Bravecto® 12 hours post-infestation against 
D. variabilis after week 6 and against A. ameri-
canum after week 3. This was due to the longer 
amount of time required to kill ticks, resulting in 
an increase in the number of live attached ticks on 
the dogs. Also, there were significantly fewer total 
(total live and dead attached) ticks (p ≤ 0.05) on the 
Seresto® treated dogs compared to the Bravecto® 
treated dogs at all time points, further illustrating 
the rapid repel and kill properties of Seresto®. 
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